Cubist maintained by Merrill Lynch at buy

Cubist Pharmaceuticals Inc. was maintained by Merrill Lynch analyst David Munno at a buy rating with a price target on the stock of $20 per share following news that patient dosing in the second of two phase II trials of HepeX-B in hepatitis B are completed and that Cubist was taking over the HepeX-B development, as planned although earlier than expected. Cubist shares Wednesday were up $0.08, or 0.47%, at $17.06 on volume of 401,760 shares versus the three-month running average of 897,022 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.